PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
The GP Service is a web and application-based platform that provides private consultations for patients across the UK. The aim is to provide a safe and easy journey for individuals who are looking for private medical treatment at their convenience and at an affordable cost. They have established a connection with over 1600 pharmacies across the UK. They have an excellent 5-star trust pilot rating and also are 1st Private Online Provider which has access to NHS Medical Records. With the proceeds, the company will scale the enterprise offering, increase brand awareness and also launch additional revenue opportunities.
days to go:
Expired
investment:
£907,540
Auto Lease Compare is a company that uses a web-based platform to provide business services of leasing cars in the UK market. The company is on a mission to transform the growing UK car leasing industry. They are currently operating in a leasing & rental market worth £49 billion in the UK alone. Auto Lease Compare have increased their users to 40,000 on the platform and have also partnered with some of the UK’s leading leasing companies. With the investment, the company will grow its business by revamping and upgrading the website, executing a strong marketing strategy and increasing brand awareness.
days to go:
Expired
investment:
£111,860
Crosspay is a company that aims to make remittance simpler and cheaper. The company built its proprietary system in 2017 to bolster international transfers at a fraction of the money charged by traditional Over-The-Counter (OTC) services. It has since powered over 50,000 transactions across 50 countries with a cumulative value of approx £32,350,000. The company aspires to become the segment leader in the more than $200 billion global remittance market. Crosspay was rated 'Excellent' on Trustpilot. It also created white-labelled apps for charities and churches to host content, broadcast live and receive donations simultaneously, irrespective of location. The company has been invited to partner on an Innovate UK project. It will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£212,581
Gendius is a company that aims to bring pharmaceuticals and health economics, through clinical research and evidence, to the mobile health market. Their latest innovation, Intellin, is an intelligent remote management diabetes platform, with over 140,000 downloads so far. The COVID-19 crisis has highlighted the need for remote home monitoring of patients, and the company feels that its product is a suitable contender in this domain. Intellin has a reliable connection to over 150 medical devices and apps, and also consists of a two-way communication setup with a healthcare professional via a secure dashboard. Gendius is registered as an approved vendor with AstraZeneca in Saudi Arabia and looks to establish deeper relations with the National Health Service (UK) to create a demand for its product. The company will use the investment to scale its business globally, drive commercialisation, offer an opportunity to its stakeholders, and target venture capital.
days to go:
Expired
investment:
£386,829
Pedal Me uses high-tech cargo bikes, trailers and trained riders to provide delivery & taxi services when needed. The company offers a solution that will out-perform motors in car-centric cities as bike-friendly measures like bike lanes are introduced. As of now, the company has 32 bikes and 45 staff in total. It has witnessed a strong MoM growth (19% on avg). The trips provided by Pedal Me has negligible carbon footprint in comparison with vans, taxis or electric vehicles. With the funds, the company will improve the technology, maintain speed with demand, develop the staff and balance the process.
days to go:
Expired
investment:
£421,330
Ziglu is a financial technology entity that allows a user to access both Forex and digital currencies seamlessly. The company permits a user to use any currency via its Mastercard debit card and protects the user's digital currency up to £50,000 against cyber-attacks. Ziglu is authorised by the UK's Financial Conduct Authority (FCA) as an Electronic Money Institution (EMI) and is one of the first companies involved with digital currencies to be registered under the UK’s Anti-Money Laundering Regulations (AMLR). The company has achieved a 94% rating on TrustPilot, offers customers the option to send money via cryptocurrency, and previously raised £5.25 million in seed funding. Ziglu has featured in media entities like Coindesk and Yahoo Finance. It will use 30% of the investment in product development, 60% on user acquisition, and 10% on international expansion initiatives.
days to go:
Expired
investment:
£3,041,878
